Tiziana Life Sciences Ltd
TLSA$148M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaLONDON, ENGLAND9 employees
Drugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
3
Next Catalyst
Aug 7, 2026
6wMarket Overview
Stock performance and key metrics
TLSA News
Catalyst Timeline
3 upcoming, 0 past
Drug Pipeline
Foralumab Nasal
Multiple System Atrophy
Foralumab
Secondary Progressive Multiple Sclerosis
Foralumab TZLS-401 100 µg
Non-Active Secondary Progressive Multiple Sclerosis
Milciclib maleate
Hepatocellular Carcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Foralumab Nasal | Phase 2 | Multiple System Atrophy | - | - |
Foralumab | Phase 2 | Secondary Progressive Multiple Sclerosis | - | - |
Foralumab TZLS-401 100 µg | Phase 2 | Non-Active Secondary Progressive Multiple Sclerosis | - | - |
Milciclib maleate | Phase 2 | Hepatocellular Carcinoma | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply